Pfizer Secures China Rights to Obesity Drug in $495 Million Deal
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market.
By Amber Tong ยท Bloomberg
Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market.